Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic variant alpha-2-macroglobulin compositions

a technology of macroglobulin and composition, which is applied in the direction of peptide/protein ingredients, peptide sources, instruments, etc., can solve the problems of inability to differentiate between acute injury and disease, difficulty in treating spinal and joint pain, and insufficient clinical evidence of acute injury. , to achieve the effect of reducing the severity, reducing the degeneration rate of tissue, and reducing the severity

Active Publication Date: 2020-05-14
CYTONICS CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a method of treating various conditions, such as cancer, degenerative diseases, traumatic diseases, and inflammatory diseases, using a composition containing an A2M variant. The composition can be administered through various methods, such as injection or surgery, and can help inhibit the activity of proteases and reduce the severity or occurrence of symptoms of the condition. The method can also increase the rate of tissue regeneration and reduce inflammation. The patent provides a variety of carriers or drugs that can be added to the composition for further treatment. Overall, the patent provides a novel way to treat various conditions using a specific composition.

Problems solved by technology

Inflammation causing spinal and joint pain can be difficult to treat.
Increasing degrees of inflammation and force applied to joints result in joint injury.
Physicians currently do not have a system or method available to differentiate between acute injury due to trauma and age related joint deteriorations.
Presently, it can be difficult to determine the appropriate course of treatment for a given patient since it can be frequently unclear whether the particular condition the patient suffers from may be acute or chronic or if pathology in the joint is the cause of the pain.
However, no clear causal pathway leading from injury or degeneration to the painful state has been confirmed.
Although some studies have provided evidence that the epidural space can be affected by an intervertebral disc herniation, none has measured concentrations of biomolecules in the epidural space in an attempt to detect the differences between affected and non-affected persons.
Injury to tendons and ligaments causes damage not only to the connective tissue, but to the extracellular matrix as well.
Damage to the ECM can interrupt cell behavior in the connective tissue and decrease and / or limit healing.
After injury, continuing damage can be caused by production of matrix metalloproteinases (MMPs) by the body.
This can lead to an imbalance between the synthesis and degradation of the ECM, as the body tries to heal itself while the enzymes remodel the ECM.
An overabundance of remodeling by MMPs cause damage to previously connected tissue which results in the formation of scar tissue.
In addition, scar tissue adhesion to surrounding tissue can cause further pulling and / or stretching of the tendons or ligaments and resultant pain.
However, these simple remedies do not always cure the injury and often more advanced treatments are needed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic variant alpha-2-macroglobulin compositions
  • Therapeutic variant alpha-2-macroglobulin compositions
  • Therapeutic variant alpha-2-macroglobulin compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

n and Selection of HEK293 Clones Expressing Recombinant A2M

[0195]Recombinant A2M wild type sequence was expressed in HEK293F cells. Hek293F cells are plated adherently and allowed to attach overnight. Cells are transfected with XTreme Gene HP (Roche) and DNA in a 6 uL reagent: 2 ug DNA ratio. Cells are grown for 48 hours at 5% CO2 and 37 degrees Celsius. Forty-eight hours after transfection media samples are taken to confirm success of the transfection via an ELISA assay that quantifies A2M protein. Cells are split so as to be in logarithmic growth phase and selection antibiotic (blasticidin) is added at 10 μg / mL (selection concentration determined experimentally). Cells are selected in antibiotic until all of the negative control cells are dead (usually about 4 to 5 days). Another media sample is taken at this point to confirm that this newly established pool is still producing protein. Upon confirmation of protein production cells are plated at a density of ˜100 cells / 10 cm dish w...

example 2

n of ADAMTS-5- and ADAMTS-4-Induced Damage of Cartilage with A2M

[0196]Bovine Cartilage Explants (BCEs) were treated with 500 ng / ml ADAMTS-5 or ADAMTS-4 for 2 days, with a 3-fold serial dilution of purified A2M (FIGS. 7A, B). Concentration of A2M tested were 100, 33.3, 11.1, 3.7, 1.2, 0.4 μg / mL. The variant A2M inhibited cartilage catabolism in a concentration dependent manner. The IC50 for inhibiting 500 ng / ml of ADAMTS-5 was calculated to be ˜7 μg / ml A2M (a 1:1 molar ratio). Maximum inhibition was observed in ˜90% with 100 μg / ml A2M (a 14:1 molar ratio). The A2M was shown to block formation of Aggrecan G3 fragments (FIGS. 7A, B) and FAC formation (FIGS. 9A-9F).

example 3

n of APIC Retentate and Filtrate

[0197]Fresh cartilage was treated with APIC containing ˜7 mg / ml A2M. Cartilage catabolism was efficiently blocked by 1% v / v of the Retentate of the APIC production process (concentration of proteins >500 kDa in size), but not by the Filtrate (contains proteins 99% of the protective factors of autologous blood.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

A2M polypeptide compositions containing a non-natural bait region are disclosed. Methods of producing wild-type and variant A2M polypeptides and polynucleotides containing a non-natural bait region are also disclosed. The bait regions of the variant A2M polypeptides demonstrate enhanced protease inhibitory characteristics compared to wild-type A2M. Variant A2M polypeptides that demonstrate longer half-lives upon administration to an organism compared to wild-type A2M are disclosed. The A2M compositions are useful in treating a number of diseases and conditions including inflammation, chronic wounds, and diseases with a pathology associated with proteases.

Description

CROSS-REFERENCE[0001]This application is a divisional of U.S. application Ser. No. 15 / 528,387, filed on May 19, 2017, pursuant to 35. U.S.C. § 371 as a United States National Phase Application of International Application PCT / 2015 / 061852, filed on Nov. 20, 2015, which claims the benefit of U.S. Provisional Application No. 62 / 082,304, filed on Nov. 20, 2014, which applications are incorporated herein by reference in their entirety.BACKGROUND OF THE INVENTION[0002]Inflammation causing spinal and joint pain can be difficult to treat. Increasing degrees of inflammation and force applied to joints result in joint injury. Abnormal joint anatomy can be a hallmark of aging, but joint injury can be also a result of trauma, such as chondral lesions often seen in athletes. While joint injury resulting from trauma can be typically associated with acute inflammation, aberrant joint anatomy resulting from aging (e.g., osteoarthritis) can be a chronic condition. Physicians currently do not have a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/81A61K45/06C12Q1/37C12P19/34A61K9/00A61K38/57
CPCG01N2500/20C12Q1/37A61K45/06A61K38/57G01N2333/811C12P19/34G01N2500/04A61K9/0019C07K14/811C07K14/8107A61P19/02A61K35/16A61K38/00A61P17/02
Inventor HANNA, LEWISLAUGHLIN, JOHN DAVIDBROWNING, SHAWN ROBERT
Owner CYTONICS CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com